

**In the claims:**

1-41. (Canceled)

42. (New) A bi-specific antibody comprising:  
 (i) a, first target recognition component which specifically binds to the inhibitory receptor IRp60 or homologues thereof; and  
 (ii) a second target recognition component which specifically binds to a marker specific for a mast cell, an eosinophil and/or a basophil.

43. (New) The bi-specific antibody of claim 42, wherein a binding of said antibody to said cell inhibits allergic-type reactions.

44. (New) The bi-specific antibody of claim 42, wherein said first and second target recognition components are linked via any one of a cross-linker, a linker compound, a carrier, a synthetic spacer, an immobilizing substrate and a (Gly<sub>4</sub>Ser)<sub>3</sub> motif based flexible region.

45. (New) The bi-specific antibody of claim 42, wherein said first and second target recognition components are cross-linked.

46. (New) The bi-specific antibody of claim 42, wherein said marker may be selected from the group consisting of immunoglobulins, Fc receptors, cytokine receptors, growth factor receptors, adhesion molecules, Ig-superfamily receptors, chemokine receptors, inflammatory mediator receptor, hormone receptors, complement factor receptors, protease-activated receptors and enzymes.

47. (New) The bi-specific antibody of claim 42, wherein said recognition component is selected from any one of a naturally occurring, synthetic or recombinant antibody, single chain Fv (scFv), bi-functional scFv, diabody, F(ab) unit, F(ab') unit, bi-specific F(ab') conjugate, chemically cross-linked bi-functional antibody, linear antibody or a F(ab')<sub>2</sub> antigen binding fragment of an antibody.

48. (New) The bi-specific antibody of claim 42, wherein said recognition component is a F(ab') unit.

49. (New) The bi-specific antibody of claim 42, wherein said marker is one of IgE, cKIT, IL-5R, CCR3 and Fc RI.

50. (New) A pharmaceutical composition comprising as an active agent the bi-specific antibody of claim 42.

51. (New) The pharmaceutical composition of claim 50, further comprising buffers, additives, stabilizers, diluents and/or excipients.

52. (New) A method of treating a disease or condition associated with mast cell and/or eosinophil and/or basophil mediated reactions, the method comprising administering to a subject in need thereof a therapeutically effective amount of a bi-specific antibody, wherein said bi-specific antibody comprises:

- (i) a, first target recognition component which specifically binds to the inhibitory receptor IRp60 or homologues thereof; and
- (ii) a second target recognition component which specifically binds to a marker specific for a mast cell, an eosinophil and/or a basophil, thereby treating the disease or condition associated with mast cell and/or eosinophil and/or basophil mediated reactions.

53. (New) The method of claim 51, wherein said disease or condition is selected from the group consisting of: allergic asthma, allergic rhinitis, allergic conjunctivitis, atopic dermatitis and atopic eczema, allergic disorders and responses to various allergens, systemic anaphylaxis, systemic mastocytosis, morphea/urticaria pigmentosa, mast cell leukemia, atherosclerosis, graft rejection, multiple sclerosis, fibrotic lung diseases, neurofibromatosis, keloids, scleroderma, rheumatoid arthritis, osteoarthritis, acute gout, ocular cicatricial pemphigoid, Crohn's disease, peritoneal adhesions, chronic graft versus host disease (GVHD), eosinophil myalgia syndrome, bronchial asthma, nasal polyposis, Wegener's granulomatosis, interstitial and other pulmonary diseases, chronic eosinophilic pneumonia, hypersensitivity pneumonitis, allergic bronchopulmonary

aspergillosis, sarcoidosis, idiopathic pulmonary fibrosis, neoplastic and myeloproliferative diseases, T cell lymphomas and Hodgkin's disease.

54. (New) The method of claim 51, wherein said disease or condition is derived from eosinophil hyperactivity or hyperplasia.

55. (New) The method of claim 51, wherein said conditions are selected from the group consisting of extrinsic bronchial asthma, allergic rhinitis, onchocercal dermatitis, atopic dermatitis, nasal polyposis, nodules, eosinophilia, rheumatism, dermatitis, and swelling (NERDS), vasculitic granulomatous diseases; temporal vasculitis, Churg-Strauss syndrome, polyarteritis, Wegener's granulomatosis, multiple sclerosis, graft rejection, bronchial asthma, interstitial and other pulmonary diseases, eosinophilic pleural effusions, transient pulmonary eosinophilic infiltrates (Löffler), histiocytosis, chronic eosinophilic pneumonia, hypersensitivity pneumonitis, allergic bronchopulmonary aspergillosis, idiopathic pulmonary fibrosis, topical eosinophilia, cat scratch disease, afebrile tuberculosis, chlamydial pneumonia at infancy, neoplastic and myeloproliferative diseases, bronchogenic carcinoma, hypereosinophilic syndrome, T cell lymphomas and Hodgkin's disease, Crohn's disease, vernal keratoconjunctivitis, juvenile inflamed conjunctivitis nevus, Kimura's disease, Gleich's disease.